Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study
Despite high frequencies of baseline resistance, substantial rates of viral suppression were maintained through Week 48 and no on-treatment resistance to study drugs was detected. These findings support the development of once-daily BIC + LEN STR to improve and optimize treatment options in individuals on complex ART.
Authors
- Nina Pennetzdorfer (ORCID: https://orcid.org/0000-0002-5468-8715)
- Vidula Naik
- Jairo Mauricio Montezuma-Rusca (ORCID: https://orcid.org/0000-0002-8391-1242)
- Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)
- Peter Sklar
- Nicolas A. Margot
Institutions
- Gilead Sciences (Spain) (ES)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- AIDS
- Published
- 2026-03-24
- DOI
- https://doi.org/10.1097/qad.0000000000004495
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00